Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
-3.23% $1.200
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 60.60 mill |
EPS: | -2.25 |
P/E: | -0.530 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 50.50 mill |
Avg Daily Volume: | 0.355 mill |
RATING 2024-04-17 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.530 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -0.530 | industry: PE 18.71 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.064 - 1.336 ( +/- 11.33%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Hall Christopher M | Buy | 400 000 | Stock Option (right to buy) |
2024-03-15 | Chen Richard | Buy | 175 000 | Stock Option (right to buy) |
2024-03-15 | Tachibana Aaron | Buy | 175 000 | Stock Option (right to buy) |
2024-03-15 | Moore Stephen Michael | Buy | 100 000 | Stock Option (right to buy) |
2024-03-01 | Myers Woodrow A Jr | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
-62.02 |
Last 98 transactions |
Buy: 3 908 824 | Sell: 9 802 248 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.200 (-3.23% ) |
Volume | 0.360 mill |
Avg. Vol. | 0.355 mill |
% of Avg. Vol | 101.45 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Date | Signal | @ |
---|---|---|
ZAP.OL | Apr 18 - 04:50 | NOK13.90 |
CODE.OL | Apr 18 - 04:49 | 0.900 |
AKBM.OL | Apr 18 - 04:45 | NOK68.40 |
BGBIO.OL | Apr 18 - 04:44 | NOK0.161 |
NEXT.OL | Apr 18 - 04:44 | NOK8.62 |
SVEG.OL | Apr 18 - 04:43 | NOK118.40 |
NORSE.OL | Apr 18 - 04:42 | NOK8.04 |
WWIB.OL | Apr 18 - 04:42 | NOK355.00 |
OETHUSD | Apr 18 - 04:53 | 2 956.98 |
STB.OL | Apr 18 - 04:40 | NOK94.50 |